Results 211 to 220 of about 101,617 (297)

Association Between SGLT2 Inhibitors and DPP‐4 Inhibitors Use and Risk of Acute Pancreatitis: Findings From Nationwide Case‐Based Analyses

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 6767-6775, August 2026.
ABSTRACT Aims The Korean national health insurance claims database was utilised to investigate the association between sodium–glucose cotransporter 2 inhibitors (SGLT2i) or dipeptidyl peptidase‐4 inhibitors (DPP‐4i) and the risk of acute pancreatitis (AP). Materials and Methods Patients with type 2 diabetes mellitus prescribed DPP‐4i or SGLT2i at least
Ye‐Jee Kim   +5 more
wiley   +1 more source

The association between COVID‐19 vaccines and bullous pemphigoid risk: A UK population‐based study

open access: yes
Journal of the European Academy of Dermatology and Venereology, EarlyView.
Mikolaj Swiderski   +7 more
wiley   +1 more source

Association Between Glucagon‐Like Peptide‐1 Receptor Agonists and Suicidality: A Systematic Review

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 6482-6508, August 2026.
ABSTRACT Aims We aimed to examine the association between GLP‐1 RA use and suicidal ideation or behaviours through a systematic review of observational studies. Materials and Methods A comprehensive search of MEDLINE, PubMed, EMBASE, CINAHL and PsycINFO was conducted from database inception through December 11, 2025. Observational studies investigating
Timothy H. Chan   +5 more
wiley   +1 more source

GIP in Cardiovascular and Kidney Disease: From Physiology to Pharmacology

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 6509-6532, August 2026.
ABSTRACT Aims To provide a comprehensive overview of the cardiovascular and renal effects of glucose‐dependent insulinotropic polypeptide (GIP) by integrating its physiological role with recent human trial data on tirzepatide, the first dual GIP and glucagon‐like peptide‐1 (GLP‐1) receptor agonist.
Michelantonio De Fano   +4 more
wiley   +1 more source

The Effects of Combined Antihypertensive and Antidiabetic Therapies on Cardiovascular Outcomes: A Systematic Review and Meta‐Analysis

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 6874-6887, August 2026.
ABSTRACT Aims Hypertension and diabetes frequently coexist, yet the net clinical impact of intentionally combining antihypertensive (AHTN) and antidiabetic (ADA) therapies on cardiovascular (CV) outcomes is uncertain. Here we quantified the effects of AHTN and ADA co‐therapy on CV and blood pressure (BP)/heart rate (HR) outcomes.
Wan Chin Hsieh   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy